Dapagliflozin and empagliflozin added to usual care for adults with nephrotic syndrome
Tests dapagliflozin or empagliflozin alongside usual care in adults with primary nephrotic syndrome.
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 75 people, planned
- Started
- 15 Nov 2025
- Planned end
- 6 Sept 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dapagliflozin
- Empagliflozin
- Standard Therapy
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary nephrotic syndrome, a kidney disease that causes a lot of protein loss in the urine. It tests dapagliflozin or empagliflozin added to standard therapy.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Primary nephrotic syndrome confirmed by a kidney biopsy (for example idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis). Kidney function (eGFR) must be ≥25 mL/min/1.73m².
- Earlier treatment
- People must be on a stable dose of immunosuppressive therapy and kidney-protecting medicines for ≥4 weeks before joining.
- Biomarker or test result
- eGFR ≥25 mL/min/1.73m² by the CKD-EPI formula.
Main reasons for not taking part
- Nephrotic syndrome caused by another disease, such as diabetes mellitus, lupus nephritis or amyloidosis
- Liver tests (ALT or AST) above 3 times the upper limit of normal
- Blood in the urine from the kidney filters (more than 10 red cells per high power field, more than 3 times in the last 2 weeks)
- Severe allergy to, or reasons not to take, dapagliflozin or empagliflozin
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult patients (≥18 years). Biopsy-confirmed primary nephrotic syndrome (e.g., idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis)
- Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m² using CKD-EPI formula
- On stable dose of immunosuppressive therapy and renoprotective agents for ≥4 weeks prior to randomization
- Able to signed informed consent
Who cannot take part
- Diagnosis of secondary nephrotic syndrome as : diabetes mellitus, lupus nephritis, and amyloidosis
- History of severe hypersensitivity or contraindications to dapagliflozin or empagliflozine
- Impaired liver functions (ALT or AST values exceeding 3 folds upper limit of normal (ULN) at the screening visit)
- Glomerular hematuria (red blood cells more than ten cells per high power field (HPF) after routine urinalysis for more than three times in the last 2 weeks)
- Pregnancy or breastfeeding
This trial is currently available in Egypt.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.
Read full original descriptionShow less
The primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes.
Participants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.
The 3 groups in the trial
- Dapagliflozin + Standard of CareTreatment being tested
Treatment: Dapagliflozin and Standard Therapy
- Empagliflozin + Standard of CareTreatment being tested
Treatment: Empagliflozin and Standard Therapy
- Standard of Care OnlyExisting treatment, for comparison
Standard treatment protocol(institutional standared) for 6 months without any additional SGLT2 inhibitor.
Treatment: Standard Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled Trial
- Plain-language title
- Dapagliflozin and empagliflozin added to usual care for adults with nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 9 June 2026